[ RadSafe ] BARDA grants $15m contract to RxBio radiomitigant countermeasure drug

S L Gawarecki slgawarecki at gmail.com
Thu Nov 10 13:46:34 CST 2011

This sounds interesting.  Anyone know what the active ingredient of
Rx100 is likely to be?  Prussian Blue?

--Susan Gawarecki

BARDA grants $15m contract to RxBio
PBR Staff Writer Published 09 November 2011

RxBio, a biopharmaceutical company which is an affiliate of University
of Tennessee Health Science Center (UTHSC), has received $15m federal
contract from Biomedical Advanced Research and Development Authority (BARDA).

The contract is valued at up to $24m for the upcoming two years.

The company expects to facilitate the development of Rx100, a
radiomitigant countermeasure drug used against lethal effects of

Rx100 has demonstrated survival benefit when administered either 24
hours before or up to 72 hours after exposure to lethal radiation

RxBio chairman and CEO McCool said the radiation countermeasure would
help save the lives numerous individuals who are exposed to lethal
levels of radiation.

More information about the RadSafe mailing list